Trials / Unknown
UnknownNCT03801135
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University Medical Centre Ljubljana · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels. The aim of study is to define coagulation status of patient after plasmapheresis with different laboratory tests and to investigate the possibility of fibrinogen concentrate replacement for the correction of induced coagulation disorder.
Conditions
- Humoral Rejection
- Guillain-Barre Syndrome
- Miller Fisher Syndrome
- CIDP
- Good Pasture Syndrome
- Hyperviscosity Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fibrinogen concentrate | Haemocomplettan will be infused after plasma exchange procedure |
| OTHER | Fresh Frozen Plasma | Fresh frozen plasma will be part of replacement fluid |
Timeline
- Start date
- 2018-10-03
- Primary completion
- 2019-09-01
- Completion
- 2019-09-24
- First posted
- 2019-01-11
- Last updated
- 2019-01-11
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT03801135. Inclusion in this directory is not an endorsement.